1 completed, 1 terminated, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Mendel Tuchman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia Carbaglu, Placebo - Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia | Phase 2 | Completed | Mendel Tuchman | 35 | 2012-09-01 | 2021-02-15 |
| Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia N-carbamylglutamate, Standard of Care - Propionic Acidemia, Methylmalonic Acidemia | Phase 2 | Terminated | Mendel Tuchman | 1 | 2012-09-01 | 2017-04-26 |
| N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia N-carbamylglutamate - Inborn Errors of Metabolism | Phase 2 / Phase 3 | Unknown | Mendel Tuchman | 52 | 2008-08-01 | 2020-02-17 |
Hyperammonemia (2) · Methylmalonic acidemia (2) · Propionic Acidemia (2) · Carbamoyl-Phosphate Synthase I Deficiency Disease (1) · Metabolism, Inborn Errors (1) · Ornithine Carbamoyltransferase Deficiency Disease (1)
carglumic acid (3) · N-carbamylglutamate (2) · Standard of Care (1)
United States (3)
R01HD058567 (1)